MG, patience is all I can say. We are in a good state of play that is for sure. Due diligence is what is required by GSK on OBJ's technology and although nothing is in concrete yet, it is a great start and hence the volatility seen today. Look beyond today's spike and reflect in 6 months time when not only GSK have further studied OBJ's technology and completed additional trial work but hopefully the FMCG's have also jumped on board.
Surges: "The GSK research centre in the UK will leak this, I'm convinced and we will see overseas money coming in."
I certainly hope this is not the case as corporate ethics is one of our biggest drivers at the moment and I certainly hope this does not occur.
Jonty
Add to My Watchlist
What is My Watchlist?